Unity Biotechnology (UBX) Competitors

Unity Biotechnology (NASDAQ:UBX) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Is UBX or CUE more profitable?

Unity Biotechnology has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Unity Biotechnology's return on equity of -119.70% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Cue Biopharma	-468.02%	-156.38%	-88.07%

Do institutionals & insiders have more ownership in UBX or CUE?

29.5% of Unity Biotechnology shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 5.8% of Unity Biotechnology shares are owned by company insiders. Comparatively, 10.8% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk and volatility, UBX or CUE?

Unity Biotechnology has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Do analysts recommend UBX or CUE?

Unity Biotechnology currently has a consensus target price of $3.75, suggesting a potential upside of 369.92%. Cue Biopharma has a consensus target price of $3.00, suggesting a potential upside of 398.34%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Cue Biopharma is more favorable than Unity Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cue Biopharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, UBX or CUE?

Unity Biotechnology has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	57.23	-$39.86M	-$1.62	-0.49
Cue Biopharma	$7.99M	5.68	-$50.73M	-$0.67	-0.90

Does the media favor UBX or CUE?

In the previous week, Cue Biopharma had 1 more articles in the media than Unity Biotechnology. MarketBeat recorded 2 mentions for Cue Biopharma and 1 mentions for Unity Biotechnology. Unity Biotechnology's average media sentiment score of 1.89 beat Cue Biopharma's score of 0.93 indicating that Unity Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Unity Biotechnology	Very Positive
Cue Biopharma	Positive

Does the MarketBeat Community prefer UBX or CUE?

Unity Biotechnology received 36 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 66.91% of users gave Unity Biotechnology an outperform vote while only 52.14% of users gave Cue Biopharma an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 182 66.91%	Underperform Votes 90 33.09%
Cue Biopharma	Outperform Votes 146 52.14%	Underperform Votes 134 47.86%

Summary

Unity Biotechnology and Cue Biopharma tied by winning 9 of the 18 factors compared between the two stocks.